243 related articles for article (PubMed ID: 17940125)
1. Effects of thiazolidinediones on bone loss and fracture.
Murphy CE; Rodgers PT
Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
[TBL] [Abstract][Full Text] [Related]
2. The effect of thiazolidinediones on BMD and osteoporosis.
McDonough AK; Rosenthal RS; Cao X; Saag KG
Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700
[TBL] [Abstract][Full Text] [Related]
3. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
Berberoglu Z; Yazici AC; Demirag NG
Clin Endocrinol (Oxf); 2010 Sep; 73(3):305-12. PubMed ID: 20148906
[TBL] [Abstract][Full Text] [Related]
6. [Thiazolidinediones and skeletal health].
Meier C; Bodmer M; Meier CR; Kraenzlin ME
Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
Grey A
Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
[TBL] [Abstract][Full Text] [Related]
11. Use of thiazolidinediones and fracture risk.
Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
[TBL] [Abstract][Full Text] [Related]
12. Vitamin A intake and osteoporosis: a clinical review.
Crandall C
J Womens Health (Larchmt); 2004 Oct; 13(8):939-53. PubMed ID: 15671709
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
[TBL] [Abstract][Full Text] [Related]
14. Bone metabolism in type 2 diabetes and role of thiazolidinediones.
Vestergaard P
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):125-31. PubMed ID: 19300092
[TBL] [Abstract][Full Text] [Related]
15. [Overview: derangement of bone metabolism in diabetes mellitus].
Takeuchi Y
Clin Calcium; 2009 Sep; 19(9):1247-55. PubMed ID: 19721195
[TBL] [Abstract][Full Text] [Related]
16. Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones SG; Momin SR; Good MW; Shea TK; Patric K
Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
[TBL] [Abstract][Full Text] [Related]
17. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials.
Zhu ZN; Jiang YF; Ding T
Bone; 2014 Nov; 68():115-23. PubMed ID: 25173606
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
[TBL] [Abstract][Full Text] [Related]
19. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
[TBL] [Abstract][Full Text] [Related]
20. Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature.
LaFleur J; McAdam-Marx C; Kirkness C; Brixner DI
Ann Pharmacother; 2008 Mar; 42(3):375-86. PubMed ID: 18230704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
